Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

Amin Ariaee; Karim Noueihad; Alex Hunter; Anthony Wignall; Hannah R. Wardill; Maya Davies; Clive A. Prestidge; Paul Joyce

doi:10.1016/j.jconrel.2026.114711

Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

Amin Ariaee
, Karim Noueihad
, Alex Hunter
, Anthony Wignall
, Hannah R. Wardill
, Maya Davies
, Clive A. Prestidge
, Paul Joyce

APC Microbiome Ireland

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Controlled Release
DOIs	https://doi.org/10.1016/j.jconrel.2026.114711
Publication status	Published - 10 Apr 2026

Access to Document

10.1016/j.jconrel.2026.114711

Cite this

@article{0c69ad408cff4ab1a884c63af3ffa349,

title = "Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery",

author = "Amin Ariaee and Karim Noueihad and Alex Hunter and Anthony Wignall and Wardill, \{Hannah R.\} and Maya Davies and Prestidge, \{Clive A.\} and Paul Joyce",

year = "2026",

month = apr,

day = "10",

doi = "10.1016/j.jconrel.2026.114711",

language = "English",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

AU - Ariaee, Amin

AU - Noueihad, Karim

AU - Hunter, Alex

AU - Wignall, Anthony

AU - Wardill, Hannah R.

AU - Davies, Maya

AU - Prestidge, Clive A.

AU - Joyce, Paul

PY - 2026/4/10

Y1 - 2026/4/10

UR - http://dx.doi.org/10.1016/j.jconrel.2026.114711

U2 - 10.1016/j.jconrel.2026.114711

DO - 10.1016/j.jconrel.2026.114711

M3 - Article

SN - 0168-3659

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

Access to Document

Other files and links

Cite this